Three cancer centers share their experiences related to the struggle of understanding wide variations in the application of sterile compounding and safe handling of oncology hazardous drugs, and the costs and operating burdens of compliance with and adherence to current pharmacy standards.
“It is time for us to bury the concept of maximum-tolerated dose in the world of targeted therapy,” according to Allen S. Lichter, MD, FASCO.
Hollywood, FL—Results from a survey of oncology pharmacists from across the country indicate that the verification process for chemotherapy orders is not uniformly electronic. In fact, >25% of responders are still using paper orders, said Carly Duncan, PharmD candidate, of the Cleveland Clinic Florida, Weston. She presented findings from her and her colleagues’ survey at the 2016 annual conference of the National Comprehensive Cancer Network.
Results 1 - 10 of 21